Camille C. Gunderson, MD, assistant professor of gynecologic oncology, Stephenson Cancer Center, discusses the use of PARP inhibitors in all-comers with ovarian cancer.
Camille C. Gunderson, MD
Advertisement
Articles by Camille C. Gunderson, MD
Camille C. Gunderson, MD, discusses the phase III open-label GOG-252 trial in advanced ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Gunderson on the GOG-252 Trial in Advanced Ovarian CancerSeptember 19th 2019
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
5